her2

News
cancer research with magnifying glass

WCLC: Bayer, Boehringer face off on HER2 cancers

Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to t

News
Bayer takes lung cancer therapy hope into phase 3

Bayer takes lung cancer therapy hope into phase 3

Bayer has advanced its small-molecule drug BAY 2927088 into phase 3 for non-small cell lung cancer (NSCLC) with HER2 activating mutations, one of the drugs central to the company’s plan to